The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists

British Journal of Dermatology

Volumn 176, Issue 2, 2017, Pages 423-430

  Tiao, J ^a,b   Feng, R ^c   Bird, S ^d   Choi, J K ^a,b   Dunham, J ^d   George, M ^d   Gonzalez Rivera, T C ^d,e   Kaufman, J L ^d   Khan, N ^a,b   Luo, J J ^f   Micheletti, R ^a   Payne, A S ^a   Price, R ^d   Quinn, C ^d   Rubin, A I ^a   Sreih, A G ^d   Thomas, P ^d   Okawa, J ^a   Werth, V P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; CUTANEOUS DERMATOMYOSITIS DISEASE AREA AND SEVERITY INDEX; DERMATOLOGIST; DERMATOMYOSITIS; FEMALE; HUMAN; INTERRATER RELIABILITY; MALE; NEUROLOGIST; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; RHEUMATOLOGIST; SCORING SYSTEM; SKIN DISEASE ASSESSMENT; ANALYSIS OF VARIANCE; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY;

ANALYSIS OF VARIANCE; DERMATOLOGISTS; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGISTS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGISTS; SEVERITY OF ILLNESS INDEX;

EID: 85007110570     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15140     Document Type: Article

References (11)

1. Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59:99–112.
2. Klein RQ, Bangert CA, Costner M et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887–94.
3. Goreshi R, Okawa J, Rose M et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132:1117–24.
4. Yassaee M, Fiorentino D, Okawa J et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010; 162:669–73.
5. Rosenbach M, Yeung H, Chu EY et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 2013; 149:550–6.
6. Rosenbach M, Murrell DF, Bystryn JC et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 129:2404–10.
7. Yeung H, Farber S, Birnbaum BK et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among Dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151:1317–22.
8. Bonilla-Martinez ZL, Albrecht J, Troxel AB et al. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144:173–80.
9. Shoukri MM. Measures of Interobserver Agreement and Reliability, 2nd edn. Boca Raton, FL: CRC Press, 2010.
10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–74.
11. Anyanwu CO, Fiorentino DF, Chung L et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 2015; 173:969–74.